Quest Diagnostics has introduced a new flow cytometry measurable residual disease (MRD) blood test for myeloma, a cancer arising from abnormal plasma cells.

The test aims to enhance ultra-sensitive detection of MRD through a non-invasive approach. It is designed to provide sensitivity comparable to next-generation sequencing methods, but at a significantly lower cost, supporting improved patient care.

The Quest test offers next-generation flow cytometry capabilities and uses only non-invasive blood samples. It does not require baseline aspirate samples as next-generation sequencing (NGS) does.